Recombinant HIV-1 virus with the indicated mutations in the protease gene. Mutations have been reported from drug resistant viral variants emerging in vivo, e.g. after treatment with the HIV protease inhibitor saquinavir
Plasmid containing entire HIV-1 (NL4-3) with the indicated mutations in the HIV-1 protease gene. The respective mutations have been identified in vivo in specimens from individuals failing antiretroviral therapy with protease inhibitors.
Plasmid contains the entire genome of HIV-1 (NL4-3) with the respective specific mutations in the protease gene. These may confer drug resistance to specific HIV protease inhibitors and have been identified in clinical specimens from individuals with therapeutic failure.
Simply ask us !One of the most interesting features of EVAg's catalogue is its flexibility, please do not hesitate to contact us by using our contact form. We can add to the catalogue tailor-made products on demand, as well as access to plateforms, or services. With the large panel of virology laboratories in our consortium, there are good chances that we would have what you are looking for.